Linezolid: safety and efficacy in special populations | Zendy

F. K. Gould | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Linezolid: safety and efficacy in special populations

Author(s) -

F. K. Gould

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr071

Subject(s) - linezolid , joint infections , medicine , pneumonia , endocarditis , intensive care medicine , staphylococcus aureus , antibiotics , surgery , vancomycin , biology , microbiology and biotechnology , arthroplasty , periprosthetic , bacteria , genetics

Linezolid has been in general use in the UK since 2000. Although toxicity, particularly haematological and neurological, has been an issue, linezolid has proved to be an effective alternative to glycopeptides in the treatment of Gram-positive infections. Since its original licence for the treatment of skin and soft tissue infections and pneumonia, there have been reports of its successful use in the treatment of bone and joint infections, endocarditis, and other difficult-to-treat infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research